ADC Therapeutics has dosed the first subject in the LOTIS-7 Phase Ib clinical trial of Zynlonta (loncastuximab tesirine-lpyl) along with other anti-cancer agents to treat relapsed or refractory B-cell non-Hodgkin lymphoma.
A CD19-directed antibody drug conjugate (ADC), Zynlonta is internalised by the cell once bound to a CD19-expressing cell.
Zynlonta received the US Food and Drug Administration (FDA) approval to treat relapsed or refractory large B-cell lymphoma in adult patients who have received two or more lines of systemic therapy.
The multi-centre, open-label, multi-arm LOTIS-7 Phase Ib clinical trial will include multiple arms in two parts, which include a dose escalation part, and a dose expansion part.
The first arm of the study will assess the activity and safety of Zynlonta along with polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma patients.
It will also assess the therapy in patients with mantle cell lymphoma, high grade B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and marginal zone lymphoma.
ADC Therapeutics chief medical officer Joseph Camardo said: “As Zynlonta has been shown in preclinical studies to have synergistic or additive effects when combined with other anti-cancer therapies, we are eager to explore the potential of our differentiated CD19-directed ADC in combination with other established therapies.
“We are excited by the opportunity to allow more lymphoma patients to achieve a response and benefit from the new combinations we are evaluating in LOTIS-7.”
In the LOTIS clinical trial programme, Zynlonta is also being assessed as a therapeutic option along with studies in other B-cell malignancies and earlier lines of therapy, said the company.
